-
公开(公告)号:US20130090612A1
公开(公告)日:2013-04-11
申请号:US13688019
申请日:2012-11-28
申请人: Eugene de Juan, JR. , Yair Alster , Cary J. Reich , K. Angela MacFarlane , Janelle Chang , Jose D. Alejandro
发明人: Eugene de Juan, JR. , Yair Alster , Cary J. Reich , K. Angela MacFarlane , Janelle Chang , Jose D. Alejandro
IPC分类号: A61F9/00
CPC分类号: A61F9/0017 , A61B17/00234 , A61K9/0051 , A61K47/34 , A61L27/025 , A61L27/16
摘要: A comfortable insert comprises a retention structure sized for placement under the eyelids and along at least a portion of conjunctival sac of the upper and lower lids of the eye. The retention structure resists deflection when placed in the conjunctival sac of the eye and to guide the insert along the sac when the eye moves. The retention structure can be configured in many ways to provide the resistance to deflection and may comprise a hoop strength so as to urge the retention structure outward and inhibit movement of the retention structure toward the cornea. The insert may move rotationally with deflection along the conjunctival sac, and may comprise a retention structure having a cross sectional dimension sized to fit within folds of the conjunctiva. The insert may comprise a release mechanism and therapeutic agent to release therapeutic amounts of the therapeutic agent for an extended time.
-
公开(公告)号:US20130066283A1
公开(公告)日:2013-03-14
申请号:US13503841
申请日:2010-10-22
申请人: Yair Alster , Hanson S. Gifford , Cary J. Reich , Eugene de Juan, JR. , John A. Scholl , Jose D. Alejandro , Douglas Sutton , Omer Rafaeli
发明人: Yair Alster , Hanson S. Gifford , Cary J. Reich , Eugene de Juan, JR. , John A. Scholl , Jose D. Alejandro , Douglas Sutton , Omer Rafaeli
IPC分类号: A61F9/01
CPC分类号: A61F9/008 , A61B18/02 , A61F9/0079 , A61F9/00804 , A61F9/009 , A61F2009/00872 , A61F2009/00893 , A61N1/36021 , A61N1/36046 , A61N1/40 , A61N7/02
摘要: Methods and apparatus for the treatment of the eye to reduce pain can treat at least an outer region of the tissue so as to denervate nerves extending into the inner region and reduce the pain. For example, the cornea of the eye may comprise an inner region having an epithelial defect, and an outer portion of the cornea can be treated to reduce pain of the epithelial defect. The outer portion of the cornea can be treated to denervate nerves extending from the outer portion to the inner portion. The outer portion can be treated in many ways to denervate the nerve, for example with one or more of heat, cold or a denervating noxious substance such as capsaicin. The denervation of the nerve can be reversible, such that corneal innervation can return following treatment.
摘要翻译: 用于治疗眼睛以减轻疼痛的方法和装置可以治疗组织的至少外部区域,以便使延伸到内部区域的神经衰老,并减轻疼痛。 例如,眼睛的角膜可以包括具有上皮缺损的内部区域,并且可以治疗角膜的外部部分以减少上皮缺损的疼痛。 角膜的外部可以被处理以将从外部延伸到内部部分的神经去激活。 外部部分可以以许多方式被治疗以使神经变性,例如用一种或多种热,冷或去神经感染的有害物质如辣椒素。 神经的去神经可以是可逆的,使得角膜神经支配可以在治疗后返回。
-
公开(公告)号:US20090099626A1
公开(公告)日:2009-04-16
申请号:US12231987
申请日:2008-09-05
申请人: Eugene de Juan, JR. , Stephen Boyd , Cary J. Reich , Christopher V. Cardenas , Tommy Jewell , Lorrie Ma , Ngoc-Tuan Nguyen
发明人: Eugene de Juan, JR. , Stephen Boyd , Cary J. Reich , Christopher V. Cardenas , Tommy Jewell , Lorrie Ma , Ngoc-Tuan Nguyen
CPC分类号: A61F9/0017 , A61B5/0031 , A61B5/06 , A61B5/411 , A61B8/0833 , A61B2562/08 , A61F9/00772 , A61F2250/0068 , A61F2250/0096 , A61L31/043 , A61L31/044 , A61L31/06 , A61L31/145 , A61L31/16 , A61L2300/404 , A61L2300/43 , G01R33/0213 , G01R33/072
摘要: This document discusses, among other things, an apparatus comprising a lacrimal implant insertable at least partially into a lacrimal punctum. The lacrimal implant comprises an implant core, and an implant body. The implant body includes a cavity sized and shaped to receive the implant core. At least one of the implant core and the implant cavity includes a detection device configured to allow automatic detection of the lacrimal implant with a separate detector device.
摘要翻译: 该文件尤其涉及一种包括可以至少部分地插入泪点的泪道植入物的装置。 泪管植入物包括植入物芯和植入体。 植入体包括尺寸和形状以容纳植入物芯的腔体。 植入物芯和植入腔中的至少一个包括检测装置,其被配置为允许用单独的检测器装置自动检测泪道植入物。
-
公开(公告)号:US20090104243A1
公开(公告)日:2009-04-23
申请号:US12231986
申请日:2008-09-05
申请人: Deepank Utkhede , Robert W. Shimizu , Rachna Jain , Stephen Boyd , Hanson S. Gifford , Eugene de Juan, JR. , Cary J. Reich
发明人: Deepank Utkhede , Robert W. Shimizu , Rachna Jain , Stephen Boyd , Hanson S. Gifford , Eugene de Juan, JR. , Cary J. Reich
CPC分类号: A61K9/0051 , A61F9/0017 , A61F9/00772 , A61F2230/0069 , A61F2250/0067 , A61K31/5575 , A61K47/34 , A61L27/54 , A61L2300/41 , A61L2300/602 , A61L2300/802 , Y02A50/395
摘要: A solid drug core insert can be manufactured by injecting a liquid mixture comprising a therapeutic agent and a matrix precursor into a sheath body. The injection can be conducted at subambient temperatures. The mixture is cured to form a solid drug-matrix core. The therapeutic agent can be a liquid at about room temperature that forms a dispersion of droplets in the matrix material. A surface of the solid drug core is exposed, for example by cutting the tube, and the exposed surface of the solid drug core releases therapeutic quantities of the therapeutic agent when implanted into the patient. In some embodiments, the insert body inhibits release of the therapeutic agent, for example with a material substantially impermeable to the therapeutic agent, such that the therapeutic quantities are released through the exposed surface, thereby avoiding release of the therapeutic agent to non-target tissues.
摘要翻译: 可以通过将包含治疗剂和基质前体的液体混合物注入鞘体来制造固体药物核心插入物。 注射可以在低于环境温度下进行。 将混合物固化以形成固体药物基质核心。 治疗剂可以是在约室温下的液体,其形成液滴在基质材料中的分散体。 固体药物核心的表面例如通过切割管而暴露,并且固体药物核心的暴露表面在植入患者体内释放治疗剂量。 在一些实施方案中,插入体抑制治疗剂的释放,例如具有对治疗剂基本上不可渗透的材料,使得治疗量通过暴露表面释放,从而避免将治疗剂释放到非靶组织 。
-
公开(公告)号:US08628792B2
公开(公告)日:2014-01-14
申请号:US13367823
申请日:2012-02-07
申请人: Deepank Utkhede , Robert W. Shimizu , Rachna Jain , Stephen Boyd , Hanson S. Gifford , Eugene De Juan, Jr. , Cary J. Reich
发明人: Deepank Utkhede , Robert W. Shimizu , Rachna Jain , Stephen Boyd , Hanson S. Gifford , Eugene De Juan, Jr. , Cary J. Reich
CPC分类号: A61K9/0051 , A61F9/0017 , A61F9/00772 , A61F2230/0069 , A61F2250/0067 , A61K31/5575 , A61K47/34 , A61L27/54 , A61L2300/41 , A61L2300/602 , A61L2300/802 , Y02A50/395
摘要: A solid drug core insert can be manufactured by injecting a liquid mixture comprising a therapeutic agent and a matrix precursor into a sheath body. The injection can be conducted at subambient temperatures. The mixture is cured to form a solid drug-matrix core. The therapeutic agent can be a liquid at about room temperature that forms a dispersion of droplets in the matrix material. A surface of the solid drug core is exposed, for example by cutting the tube, and the exposed surface of the solid drug core releases therapeutic quantities of the therapeutic agent when implanted into the patient. In some embodiments, the insert body inhibits release of the therapeutic agent, for example with a material substantially impermeable to the therapeutic agent, such that the therapeutic quantities are released through the exposed surface, thereby avoiding release of the therapeutic agent to non-target tissues.
摘要翻译: 可以通过将包含治疗剂和基质前体的液体混合物注入鞘体来制造固体药物核心插入物。 注射可以在低于环境温度下进行。 将混合物固化以形成固体药物基质核心。 治疗剂可以是在约室温下的液体,其形成液滴在基质材料中的分散体。 固体药物核心的表面例如通过切割管而暴露,并且固体药物核心的暴露表面在植入患者体内释放治疗剂量。 在一些实施方案中,插入体抑制治疗剂的释放,例如具有对治疗剂基本上不可渗透的材料,使得治疗量通过暴露表面释放,从而避免将治疗剂释放到非靶组织 。
-
公开(公告)号:US20100114309A1
公开(公告)日:2010-05-06
申请号:US12521543
申请日:2007-12-21
IPC分类号: A61F2/16
CPC分类号: A61F9/0017 , A61F9/00772 , A61F9/00781 , A61K9/0051
摘要: An implant for use with an eye comprises an implantable structure and a therapeutic agent. The therapeutic agent is deliverable from the structure into the eye so as to therapeutically effect and/or stabilize a refractive property of the eye. In many embodiments, the refractive property of the eye may comprise at least one of myopia, hyperopia or astigmatism. The therapeutic agent can comprise a composition that therapeutically effects or stabilizes the refractive property of the eye. The therapeutic agent may comprise at least one of a mydriatic or a cycloplegic drug. For example, the therapeutic agent may include a cycloplegic that comprises at least one of atropine, cyclopentolate, succinylcholine, homatropine, scopolamine, or tropicamide. In many embodiments, a retention element can be attached to the structure to retain the structure along a natural tissue surface.
摘要翻译: 用于眼睛的植入物包括可植入结构和治疗剂。 治疗剂可以从结构递送到眼睛中,以便治疗影响和/或稳定眼睛的折射性质。 在许多实施例中,眼睛的屈光性可以包括近视,远视或散光中的至少一种。 治疗剂可以包含治疗影响或稳定眼睛的折射性质的组合物。 治疗剂可以包括散瞳剂或瘫痪药物中的至少一种。 例如,治疗剂可以包括睫状肌麻痹症,其包括阿托品,环戊二酸酯,琥珀酰胆碱,同质素,东莨菪碱或托品酰胺中的至少一种。 在许多实施例中,保持元件可以附接到结构以沿着天然组织表面保持结构。
-
公开(公告)号:US09011361B2
公开(公告)日:2015-04-21
申请号:US12231987
申请日:2008-09-05
申请人: Eugene de Juan, Jr. , Stephen Boyd , Cary J. Reich , Christopher V. Cardenas , Tommy Jewell , Lorrie Ma , Ngoc-Tuan Nguyen
发明人: Eugene de Juan, Jr. , Stephen Boyd , Cary J. Reich , Christopher V. Cardenas , Tommy Jewell , Lorrie Ma , Ngoc-Tuan Nguyen
IPC分类号: A61M5/00 , A61M35/00 , A61M31/00 , A61K9/22 , A61M29/00 , A61M37/00 , A61F9/007 , A61B5/06 , A61F9/00 , G01R33/02 , G01R33/07 , A61B5/00 , A61B8/08
CPC分类号: A61F9/0017 , A61B5/0031 , A61B5/06 , A61B5/411 , A61B8/0833 , A61B2562/08 , A61F9/00772 , A61F2250/0068 , A61F2250/0096 , A61L31/043 , A61L31/044 , A61L31/06 , A61L31/145 , A61L31/16 , A61L2300/404 , A61L2300/43 , G01R33/0213 , G01R33/072
摘要: This document discusses, among other things, an apparatus comprising a lacrimal implant insertable at least partially into a lacrimal punctum. The lacrimal implant comprises an implant core, and an implant body. The implant body includes a cavity sized and shaped to receive the implant core. At least one of the implant core and the implant cavity includes a detection device configured to allow automatic detection of the lacrimal implant with a separate detector device.
-
公开(公告)号:US10166142B2
公开(公告)日:2019-01-01
申请号:US14236863
申请日:2012-08-03
申请人: Eugene De Juan, Jr. , Yair Alster , Kathleen Cogan Farinas , K. Angela MacFarlane , Cary J. Reich , Randolph E. Campbell , Signe Erickson
发明人: Eugene De Juan, Jr. , Yair Alster , Kathleen Cogan Farinas , K. Angela MacFarlane , Cary J. Reich , Randolph E. Campbell , Signe Erickson
IPC分类号: A61F9/00 , A61K9/00 , A61K31/382 , A61K31/407 , A61K31/519
摘要: A therapeutic device that can release a therapeutic agent comprising a porous structure coupled to a container comprising a reservoir. The reservoir can comprise a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in a patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. The length of the channels extending from the first side to the second side may comprise an effective length greater than a distance across the porous structure from the first side to the second side. The therapeutic device may comprise a penetrable barrier to inject therapeutic agent into the device when implanted in the patient.
-
公开(公告)号:US20140358125A1
公开(公告)日:2014-12-04
申请号:US14236863
申请日:2012-08-03
申请人: Eugene de Juan, JR. , Yair Alster , Kathleen Cogan Farinas , K. Angela MacFarlane , Cary J. Reich , Randolph E. Campbell , Signe Erickson
发明人: Eugene de Juan, JR. , Yair Alster , Kathleen Cogan Farinas , K. Angela MacFarlane , Cary J. Reich , Randolph E. Campbell , Signe Erickson
IPC分类号: A61F9/00 , A61K31/382
CPC分类号: A61F9/0017 , A61F2250/0031 , A61F2250/0068 , A61K9/0051 , A61K31/382 , A61K31/407 , A61K31/519 , F04C2270/041
摘要: A therapeutic device that can release a therapeutic agent comprising a porous structure coupled to a container comprising a reservoir. The reservoir can comprise a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in a patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. The length of the channels extending from the first side to the second side may comprise an effective length greater than a distance across the porous structure from the first side to the second side. The therapeutic device may comprise a penetrable barrier to inject therapeutic agent into the device when implanted in the patient.
摘要翻译: 一种能够释放治疗剂的治疗装置,所述治疗剂包括与包含储存器的容器相连的多孔结构。 贮存器可以包含一定量的体积,当耦合到多孔结构并且植入患者体内时,释放处理量的治疗剂延长时间。 所述多孔结构可以包括联接到所述储存器的第一侧和与所述患者联接以释放所述治疗剂的第二侧。 从第一侧延伸到第二侧的通道的长度可以包括大于多孔结构从第一侧到第二侧的距离的有效长度。 治疗装置可以包括当植入患者时将治疗剂注射到装置中的可穿透屏障。
-
公开(公告)号:US20140031769A1
公开(公告)日:2014-01-30
申请号:US13988298
申请日:2011-11-18
申请人: Eugene de Juan, JR. , Yair Alster , Steven M. Chamow , Kathleen Cogan Farinas , K. Angela MacFarlane , Cary J. Reich , Randolph E. Campbell , Signe Erickson , Blaine Bueche
发明人: Eugene de Juan, JR. , Yair Alster , Steven M. Chamow , Kathleen Cogan Farinas , K. Angela MacFarlane , Cary J. Reich , Randolph E. Campbell , Signe Erickson , Blaine Bueche
IPC分类号: A61F9/00
CPC分类号: A61F9/0017 , A61K9/0051 , A61K9/1647 , A61K9/1652 , A61K31/573
摘要: An injectable formulation of therapeutic agent may comprise the therapeutic agent and a stabilizer such that a substantial portion of the stabilizer remains in the therapeutic device to stabilize the therapeutic agent when the therapeutic agent is released from the therapeutic device. The injectable formulation may comprise one or more of binding agent particles or erodible material particles, such that the formulation can be injected into the therapeutic device. The binding agent particles can bind reversibly to the therapeutic agent so as to modulate release of the therapeutic agent, and the erodible material particles can generate protons of an acid so as to increase stability of the therapeutic agent and may modulate release of the therapeutic agent. The therapeutic agent can be combined with one or more of the stabilizer, the binding agent particles or the erodible particles to increase stability of the therapeutic agent and may modulate release.
摘要翻译: 治疗剂的可注射制剂可以包含治疗剂和稳定剂,使得当治疗剂从治疗装置释放时,大部分稳定剂保留在治疗装置中以稳定治疗剂。 可注射制剂可以包含一种或多种粘合剂颗粒或可侵蚀材料颗粒,使得可以将制剂注射到治疗装置中。 结合剂颗粒可以可逆地结合治疗剂以调节治疗剂的释放,并且可侵蚀的材料颗粒可以产生酸的质子,以增加治疗剂的稳定性并且可以调节治疗剂的释放。 治疗剂可以与稳定剂,结合剂颗粒或可侵蚀颗粒中的一种或多种组合以增加治疗剂的稳定性并且可以调节释放。
-
-
-
-
-
-
-
-
-